Drug Trial Radar · NCT04143711
Study of DF1001 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
270
Actual
Start
Nov 11, 2019
Primary completion
Dec 5, 2025
Study completion Dec 5, 2025
Sponsor
- Lead sponsor
- Dragonfly TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express human epidermal growth factor receptor 2 (HER2). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible patients having either HER2 activated non-small cell lung cancer, hormone receptor (HR) positive HER2 negative metastatic breast cancer, or HER2 positive metastatic breast cancer. DF1001-001 will be administered as monotherapy or in combination; combinations are DF1001 + nivolumab, DF1001 + Nab paclitaxel, and DF1001 + sacituzumab govitecan-hziy.
Conditions
- Solid Tumor, Adult
Interventions
DF1001Drug
Immunotherapy agent targeting NK cells.
NivolumabDrug
Anti-PD-1 immunotherapy agent
Nab paclitaxelDrug
A chemotherapy treatment combining paclitaxel with albumin
Sacituzumab Govitecan-hziyDrug
A Trop-2 (Tumor-associated calcium signal transducer 2) directed antibody and topoisomerase inhibitor drug conjugate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of number of dose limiting toxicities experienced on study as defined per criteria in the study protocolTime frame: First 3 weeks of treatment for each subject.
- Assess Overall Response RateTime frame: Through 90 days after completion of the study, an average of 1 year.
- Assess number of adverse events observed during treatment with DF1001 in combination with NivolumabTime frame: Screening visit up to 28 days after last treatment on study.
- Assess number of adverse events observed during treatment with DF1001 in combination with Nab paclitaxelTime frame: Screening visit up to 28 days after last treatment on study.
- Assess number of adverse events observed during treatment with DF1001 in combination with Sacituzumab govitecan-hziyTime frame: Screening visit up to 28 days after last treatment on study.
Locations
44 sites in 6 countries. Site status is shown where the registry gives one.
University of California Irvine Medical Center
Irvine, California
University of Southern California
Los Angeles, California
Sharp Healthcare
San Diego, California
University of California San Francisco
San Francisco, California
University of Kansas Medical Center Research Institute, Inc.
Westwood, Kansas
Louisiana State University
New Orleans, Louisiana
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center
New York, New York
Montefiore Einstein Center for Cancer Care
The Bronx, New York
University Hospitals Cleveland Medical Center
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
Rhode Island Hospital
Providence, Rhode Island
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Multicare Health System Tacoma General Hospital
Tacoma, Washington
University of Wisconsin
Madison, Wisconsin
Centre Hospitalier de l'Ardenne
Arlon, Belgium
Grand Hopital de Charleroi
Charleroi, Belgium
Domaine Universitaire du Sart Tilman; CHU de Liege
Liège, Belgium
Herlev og Gentofte Hospital
Herlev, Denmark
Rigshospitalet
Copenhagen, Capital Region, Denmark
Groupe Hospitalier Saint Andre
Bordeaux, France
Centre Oscar Lambret
Lille, France
Centre Leon Berard
Lyon, France
Institut Paoli Calmettes
Marseille, France
Institut Regional du Cancer de Montepelier
Montpellier, France
ICO - Site Rene Gauducheau
Saint-Herblain, France
Institut Claudius Regaud
Toulouse, France
Institut Curie
Paris, Paris, France
Amsterdam University Medical Center
Amsterdam, Netherlands
Universitair Medisch Centrum Groningen
Groningen, Netherlands
Maasticht University Medical Center
Maastricht, Netherlands
Radboud University Nijmegen
Nijmegen, Netherlands
Erasmus University Medical Center
Rotterdam, Netherlands
UMC Utrecht
Utrecht, Netherlands
Inje University Haeundae Paik Hospital
Busan, South Korea
National Cancer Center
Goyang-si, South Korea
Ajou University Hospital
Gyeonggi-do, South Korea
CHA Bundang Medical Center, CHA University
Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam, South Korea
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.